Plasma-based NGS has also demonstrated clinical utility in detecting targetable alterations and characterising resistance mechanisms after progression with ALK inhibitors in ALK-rearranged NSCLC patients [62, 63]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.